Wassim El Harake, MD
Endocrinology, Diabetes & Metabolism · Joliet, ILNPI 1346236098
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,058 of the $16,769 with a category attached, or 89.8%. It is spread thinly across 44 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations.
Across 825 payments — averaging $20.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Novo Nordisk$2K
- AbbVie$2K
- Lilly USA, LLC$1K
- Sanofi-aventis U.S. LLC$1K
- AstraZeneca$994
- plus $7K from 38 others
What the payments were for
- Consulting fees$1,5759%
- Food & beverage$15,05890%
- Education$770%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$1,680
- FARXIGA$340
- DEXCOM G6 TRANSMITTER$252
- TOUJEO$228
- SOLIQUA 100/33$228
- Ozempic$224
- Korlym$209
- TZIELD$167
- Kerendia$128
- Pogo Automatic Blood Glucose Monitoring System$124
- EVENITY$121
- JARDIANCE$113
- Omnipod$109
- FreeStyle Libre$106
- RYBELSUS$102
How this compares
$16,769 in reported general payments places this provider in the 85th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 92 | $96,816 |
| FarxigaDapagliflozin Propanediol | 91 | $86,720 |
| ZenpepLipase/Protease/Amylase | 19 | $60,399 |
| OzempicSemaglutide | 42 | $55,161 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 61 | $50,637 |
| TrulicityDulaglutide | 44 | $46,946 |
| JanuviaSitagliptin Phosphate | 39 | $42,524 |
| RybelsusSemaglutide | 20 | $19,394 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $17,629 |
| KerendiaFinerenone | 24 | $15,418 |
| MounjaroTirzepatide | 14 | $14,883 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $14,341 |
| Humalog Kwikpen U-100Insulin Lispro | 51 | $12,544 |
| Novolog FlexpenInsulin Aspart | 32 | $9,985 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 20 | $9,485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $839 | $96,81692 claims |
| AstraZenecaFarxiga | $994 | $86,72091 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $1,964 | $82,98585 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,308 | $61,82958 claims |
| MerckJanuvia | $453 | $42,52439 claims |
| BayerKerendia | $401 | $15,41824 claims |
| Sanofi-aventis U.S. LLCLantus | $1,158 | $4,43021 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $55 | $2,537221 claims |
| AbbVieSynthroid | $1,538 | $96319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Joliet
- Babak PazookiJoliet$582K
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Ammar BayrakdarEvergreen Park$517K
- George BakrisChicago$403K
- Terrence SwadeLombard$369K
- Wenyu HuangChicago$341K
- Liana BillingsSkokie$295K
- Daniel SoArlington Heights$283K
- Silvana PannainChicago$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.